Abcam PLC (NASDAQ:ABCZY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Tuesday. The firm presently has a $16.00 price target on the stock. Zacks Investment Research‘s target price would indicate a potential upside of 15.71% from the stock’s current price.
According to Zacks, “Abcam PLC distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam PLC is headquartered in Cambridge, the United Kingdom. “
Abcam PLC (NASDAQ ABCZY) opened at 13.8275 on Tuesday. The firm’s 50-day moving average price is $14.16 and its 200 day moving average price is $12.78. Abcam PLC has a 52-week low of $9.13 and a 52-week high of $15.22. The firm has a market cap of $2.82 billion and a PE ratio of 50.4653.
TRADEMARK VIOLATION WARNING: “Zacks Investment Research Upgrades Abcam PLC (ABCZY) to “Buy”” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/10/05/zacks-investment-research-upgrades-abcam-plc-abczy-to-buy.html.
Receive News & Ratings for Abcam PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam PLC and related companies with MarketBeat.com's FREE daily email newsletter.